HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Rejects 8 Health Claims For Foods In 2022, Authorizes None

Executive Summary

Five general function health claims, two for the reduction of disease risk and one for children's development or health were rejected by the European Commission in 2022 after applicants failed to establish a cause and effect relationship between the food and the claimed effect.

You may also be interested in...



EU Authorizes Cholesterol Lowering Health Claim For Supplement After 10 Year Wait

France's Laboratoire Lescuyer can now claim its Limicol botanical extract supplement "reduces blood LDL-cholesterol concentrations" after waiting more than 10 years for approval by the European Commission.

Clasado Begins European Expansion Of Bimuno Prebiotic With Italy And San Marino

Prebiotic manufacturer Clasado has struck a deal to bring its Bimuno brand to Europe's most liberal biotics market, Italy, as well as neighboring San Marino. It's the first move in an international expansion strategy which will eventually take Clasado to the US and Asia.

UK Rejects Blood Glucose Health Claim For White Mulberry Supplement

The UK Nutrition and Health Claims Committee has rejected the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for Ascarit’s white mulberry-based dietary supplement. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel